Baeuerle PA, Henkel T (1994): Function and activation of NF-kappa B
in the immune system. Annu Rev Immunol 12:141–179.
Bazan NG, Fletcher BS, Herschman HR, Mukherjee PK (1994):
Platelet-activating factor and retinoic acid synergistically activate the inducible prostaglandin synthase gene. Proc Natl Acad
Sci USA 91:5252–5256.
Behl C, Davis JB, Lesley R, Schubert D (1994): Hydrogen peroxide
mediates amyloid beta protein toxicity. Cell 77:817–827.
Boissiere F, Hunot S, Faucheux B, Duyckaerts C, Hauw JJ, Agid Y,
Hirsch EC (1994): Nuclear translocation of NF-kappa B in
cholinergic neurons of patients with Alzheimer's disease. Neuroreport 8:2849–2852.
Brostjan C, Anrather J, Csizmadia V, Stroka D, Soares M, Bach FH,
Winkler H (1996): Glucocorticoid-mediated repression of NF- kappa B activity in endothelial cells does not involve induction
of I kappa B alpha synthesis. J Biol Chem 271:19612–19616.
Browning DD, Pan ZK, Prossnitz ER, Ye RD (1997): Cell type- and
developmental stage-specific activation of NF-kappa B by f
Met-Leu-Phe in myeloid cells. J Biol Chem 272:7995–8001.
Cai W, Hu L, Foulkes JG (1996): Transcription-modulating drugs:
Mechanism and selectivity. Curr Opin Biotechnol 7:608–615.
Carter BD, Kaltschmidt C, Kaltschmidt B, Offenhauser N, BohmMatthaei R, Baeuerle PA, Barde YA (1996): Selective activation
of NF-kappa B by nerve growth factor through the neurotrophin
receptor p75. Science 272:542–545.
Dickson DW, Lee SC, Mattiace LA, Yen SH, Brosnan C (1993):
Microglia and cytokines in neurological disease, with special
reference to AIDS and Alzheimer's disease. Glia 7:75–83.
Dollard SC, James HJ, Sharer LR, Epstein LG, Gelbard HA, Dewhurst
S (1995): Activation of nuclear factor kappa B in brains from
children with HIV-1 encephalitis. Neuropathol Appl Neurobiol
21:518–528.
Du Yan S, Zhu H, Fu J, Yan SF, Roher A, Tourtellotte WW,
Rajavashisth T, Chen X, Godman GC, Stern D, Schmidt AM
(1997): Amyloid-beta peptide-receptor for advanced glycation
endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in
Alzheimer disease. Proc Natl Acad Sci USA 94:5296–5301.
Fujita T, Nolan GP, Ghosh S, Baltimore D (1992): Independent modes
of transcriptional activation by the p50 and p65 subunits of
NF-kappa B. Genes Dev 6:775–787.
Goldgaber D, Harris HW, Hla T, Maciag T, Donnelly RJ, Jacobsen JS,
Vitek MP, Gajdusek DC (1989): Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci USA 86:7606–7610.
Grilli M, Goffi F, Memo M, Spano P (1996): Interleukin-1 beta and
glutamate activate the NK-kappa B/Rel binding site from the
regulatory region of the amyloid precursor protein gene in
primary neuronal cultures. J Biol Chem 271:15002–15007.
Grilli M, Pizzi M, Memo M, Spano P (1997): Neuroprotection by
aspirin and sodium salicylate through blockade of NF-kappa B
activation. Science 274:1383–1385.
Guerrini L, Molteni A, Wirth T, Kistler B, Blasi F (1997): Glutamatedependent activation of NF-kappa B during mouse cerebellum
development. J Neurosci 17:6057–6063.
Helenius M, Hanninen M, Lehtinen SK, Salminen A (1996): Changes
associated with aging and replicative senescence in the regulation of transcription factor nuclear factor-kappa B. Biochem J
318:603–608.
Hensley K, Butterfield DA, Hall N, Cole P, Subramaniam R, Mark R,
Mattson MP, Markesbery WR, Harris ME, Aksenov M, et al.
(1996): Reactive oxygen species as causal agents in the
neurotoxicity of the Alzheimer's disease-associated amyloid
beta peptide. Ann NY Acad Sci 786:120–134.
Hla T, Neilson, K (1992): Human cyclooxygenase 2 cDNA. Proc Natl
Acad Sci USA 89:7384–7388.
